Critical Path Institute

C-Path leads collaborations that accelerate drug development, advancing better treatments for people worldwide.

C-Path is an indispensable partner of excellence in medical product development worldwide, shaping i

Goal One: As C-Path’s leadership looks to the future, we are excited to take on new programs that focus on unmet needs in specific disease areas or disciplines where our expertise can make significant impact.

Goal Two: We are prepared to expand our work to encompass new areas of cutting-edge regulatory science.

Goal Three: We are committed to bringing more global expertise and seeking new strategic alliances that will benefit programs or enter areas of unmet need and are compatible with our mission and values.

Critical Path Institute invests in quarterly leadership training for all people managers. This is organized by the human resources department and involves bringing outside vendors in who specialize in leadership training.

As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical outcomes. Health care professionals use drugs in novel ways as a potential life-saving intervention when no specific approved therapies are available. However, without the ability to share these experiences in a systematic manner, the clinical and research communities cannot benefit from lessons learned. To address the challenge, Critical Path Institute (C-Path) announced the launch of the CURE Drug Repurposing Collaboratory (CDRC) funded by the U.S. Food and Drug Administration (FDA), in collaboration with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). A public-private partnership, CDRC will provide a forum for the exchange of clinical practice data to inform potential new uses of existing drugs for areas of high unmet medical need, advancing research in these areas. The Collaboratory will also create a network connecting major treatment centers, academic institutions and researchers, private practitioners, government facilities and health care professionals around the world. In a pilot project focused on COVID-19, CDRC will use data collected via the CURE ID platform to aggregate global clinician treatment experiences to identify existing drugs that demonstrate possible treatment approaches that should be studied further in randomized trials. Critical updates have been made to the CURE ID case report form for capturing relevant details related to COVID-19.